로딩 중…
StockDiggingStockDigging

AstraZeneca PLC

AZN· NYSE
GBGB
$166.04-0.06%
2026-09-18

Financials

Valuation Metrics

AstraZeneca PLC's Market Cap is $257.51B. At end of 2025 it was $141.02B. Ranked #54 of 3,121 in US market (top 2%), #32 of 1,658 on NYSE (top 2%), #6 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$257.51B
Revenue$61.37B
Net Income$10.45B
Total Assets$115.70B
Net Assets$50.24B
Employees96,100
Value
P/E24.65x
P/B5.13x
PEG0.95x
P/S4.20x
EV/EBITDA13.78x
FCF Yield3.39%
Profitability
ROE20.79%
ROA9.03%
Op. Margin22.77%
Revenue Growth8.61%
Earnings Growth25.93%
Financial Health
Debt Ratio130.16%
Total Debt$32.20B
FCF$8.74B
Cash$4.89B
Current Ratio0.89x
Net Debt/EBITDA1.32x
Dividend
Div. Yield1.91%
Div. Growth9.78%
Performance
1Y Return8.85%
1M Return0.66%
From 52W High-21.12%
1Y MDD-25.41%
Trading
Volume2,557,489 shares
Trading Value$426M
Per Share
EPS$6.74
BPS$32.39

Company Info

CEO Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
Employees 96,100
HQ Cambridge, United Kingdom

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.